While we were unable to demonstrate statistical significance, our result is consistent with preclinical data in which successful anti-angiogenic treatment has been shown to inhibit VEGFR2, decrease tumor vessel number and density based on immunohistochemistry in xenograft and preclinical models [30,31,32,33]. Here, KDR is linked to neoplasm.